Stress Urinary Incontinence Clinical Trial
Official title:
Optimizing Treatment Outcomes for Women With Stress Urinary Incontinence Through the Identification of Factors Contributing to Successful Interventions
Urinary incontinence (UI) affects up to 50% of adult populations and stress urinary
incontinence (SUI) is the most common form of UI, accounting for approximately 60% of
patients. Women are affected by SUI much more often than men. Urine leakage in women with SUI
occurs on exertion or during tasks that increase pressure on the bladder such as sneezing or
coughing. SUI has been shown to be a barrier to physical activity in women, and as such can
contribute to the development of diseases and disorders associated with inactivity.
SUI appears to have many contributing factors such as structural damage (eg. tears in the
pelvic organ supporting tissues), muscle weakness related to nerve injury or aging, or
thinning of the urethral wall and/or its surrounding muscular sphincters. Currently the most
common treatments for SUI are conservative therapy, which normally takes the form of exercise
therapy provided by specialized nurses or physical therapists, and surgery, which is aimed at
enhancing urethral support. Exercise therapy is effective, resulting in complete cure in 50%
of cases, and surgery is effective for approximately 80% of patients but carries risks such
as the development of urinary retention. It is currently not clear which treatment approach
is better for which women.
Through the proposed research, the investigators aim to determine how to predict which
patients will improve or be cured with exercise therapy such that surgery can be avoided.
Specifically the investigators will determine what is different between patients in whom
exercise therapy succeeds and in whom exercise therapy fails. The investigators will also
determine whether physiotherapist-supervised training of the pelvic floor muscles before
surgery improves surgical outcomes. The proposed research will enable us to better understand
the female continence system and how it responds to physiotherapeutic intervention. It will
help us to develop improved assessment procedures that can streamline patient management.
It is hypothesized that participants in the physical therapy group will demonstrate greater
improvements in pelvic floor muscle (PFM) function after treatment when compared to the
control group. It is also expected that women in the physical therapy group will show better
post-surgical outcomes when compared to the control group. The investigators will also
develop and test a predictive model to identify those women with SUI who will benefit from
physical therapy.
Objective 1: to evaluate characteristics predictive of the success or failure of PFM training
in women with SUI.
To meet this objective, a cohort study will be used. Women with SUI will be recruited
prospectively, will provide demographic information, will undergo a clinical evaluation of
their PFM strength, will fill out the International Consultation on Incontinence
Questionnaires (ICIQs), and will undergo an extensive evaluation of their continence system
using ultrasound imaging. Ultrasound imaging will be used to measure muscle morphology (the
presence and extent of PFM defect, PFM cross sectional area, urethral sphincter cross
sectional area), fascial support (position of the bladder neck at rest and on Valsalva
maneuver) and urethral mobility (amount of excursion of the urethra on coughing). A
predictive multivariate binary logistic regression model will be developed to determine
whether demographic variables, PFM strength, PFM morphology measures, fascial support or
urethral mobility measured prior to the intervention can predict which women with SUI are
cured after a standardized 12-week physical therapy program aimed at improving the strength,
power, endurance and motor control of the PFMs.
Objective 2: to determine whether a program of pre- and peri-operative physical therapy aimed
at improving the strength and motor control of the PFMs improves surgical outcomes relative
to usual care in women with predominant symptoms of SUI.
Women who are waiting for surgery to treat symptoms of SUI at two hospital sites will be
randomized to either a physical therapy group or a control group. Women assigned to the
physical therapy group will receive a standardized 12 week program of PFM training prior to
their surgery, will continue with these exercises until they undergo surgery, and will resume
their exercises after surgery. The control group will receive usual care, which is a handout
describing PFM exercises. The primary outcome of this study will be reported scores on
patient-oriented ICIQs, which will be completed on entering the study, twelve weeks later,
and at surgical follow up visit 12 weeks after surgery. Analysis of variance models will be
used to compare outcomes between the physiotherapy group and the control group both before
surgery and at 12 weeks after surgery. Chi Square models will assess whether cure rates are
higher in women belonging to the physical therapy as compared to the control group.
Taken together, the results will direct clinical decision making around the delivery of
appropriate interventions for women with SUI, particularly physical therapy and TVTand TVT-O
surgery.
DESCRIPTION OF METHODS AND PROCEDURES
a) Study Design and Methodology: Subjects and Screening All women above the age of 18 who
report symptoms of SUI and who have been evaluated by a urogynaecologist (Dr. M.A.Harvey or
Dr. S. Johnston) at Kingston General Hospital (KGH), (Dr. K. Baker) at the Ottawa Hospital,
(Dr. Magali Robert) at the Foothills Hospital in Calgary or (Dr. V. della Zazzera) at the
Montfort Hospital in Ottawa and who have been deemed appropriate for TVT or TVT-O surgery and
have decided to pursue this option will be asked by their physician if they are willing to be
contacted by the investigators. For those who agree, they will receive a follow-up phone call
to determine their interest in participating and, if appropriate, their eligibility. Eligible
and interested participants will be instructed on how to complete a three-day bladder diary
to record the number of daily episodes of urine leakage experienced over a typical three day
period.
Volunteers will be scheduled to attend a baseline evaluation at the Pelvic Floor Laboratory
at Queen's University or at the Dr. Linda McLean's Pelvic Floor Laboratory at the University
of Ottawa. At this first visit, eligibility of the participant will be confirmed based on the
bladder diary results (they must have experienced at least one episode of urine leakage over
the three-day diary), a pad test and the absence of evidence of any neurological cause of
pelvic floor muscle dysfunction.
Those who are still eligible will have their height and weight recorded, and bladder volume
will be measured using trans-abdominal ultrasound (US) imaging. If the bladder volume is at
least 250 ml, then the participant will begin a standardized pad test (i.e., a circuit of
walking and stair climbing for 30 minutes, which has been shown to be highly sensitive and
specific to the diagnosis of urinary incontinence. If the bladder volume is less than 250mL,
the volunteer will be asked to drink 350mL of water and will wait until proper volume is
attained. In this case, the volunteer will complete the study questionnaires described below
while waiting for her bladder to fill. Once her bladder has been filled to 250mL, she will
then begin the test. For the test, an incontinence pad will be weighed and adhered to her
undergarment. The woman will then perform a standardized circuit of walking and stair
climbing for 30 minutes, after which time the weight of the pad will be measured again. An
increase in weight greater than 1g will confirm the presence of urine leakage and will
confirm the participant's eligibility. If the participant is deemed ineligible at this point,
she will be thanked for her participation and withdrawn from the remainder of the study.
At this point, volunteers who meet the bladder diary and pad test requirements will undergo
an urogynecological screening exam by a research assistant.. This physical screening includes
palpation to rule out pelvic mass(es), manual muscle testing to evaluate PFM strength, and
sensory and reflex testing to rule out neurologic causes of incontinence. This will
constitute the last step to evaluate participant's eligibility. If the participant has no
evidence of pelvic mass or neurologic defects, all criteria are met, and the woman will enter
the study.
At this same session, eligible participants will undergo a three-dimensional (3D) US imaging
assessment of her pelvic region. Ultrasound imaging will be performed first in the lithotomy
position using a transvaginal endoprobe to evaluate the urethral sphincter. Next, using a 3D
curvilinear transducer, the PFMs will be visualized in the axial plane while the participant
performs three repetitions of a maximal voluntary contraction. A 2D curvilinear transducer
will then be used to capture video clips in the sagittal plane while the participant performs
three repetitions of a Valsalva maneuver, and of a cough. The participant will then move to a
standing position with a wide stance to allow for the curvilinear transducer to be applied
against her perineum. She will be asked to repeat three repetitions of the Valsalva maneuver,
and three repetitions of a maximal effort cough. This will conclude the US imaging testing
section.
If they have not already been completed, the participant will conclude this session by
completing the International Consultation on Incontinence Questionnaires (ICIQs) to evaluate
their incontinence symptoms, and each participant will be given a standard educational sheet
describing how to perform PFM strengthening exercises. They will be advised that they will be
contacted to inform them whether they have been randomized to the physical therapy or control
group. The entire baseline testing will take approximately 2.5 hours.
Randomization: Participants will be randomly assigned (1:1) to either the physical therapy
group or the control group using a secure web-based computerized randomization system which
will conceal future randomizations. Randomization will be stratified by site using permuted
blocks of random size. Participant blinding is not possible in a study of this nature,
however the research assistant performing the pre- and post-treatment assessments will remain
blinded to group assignment during all data collection and processing.
Interventions: A total of 400 volunteers will be randomly assigned to each of the two
experimental groups: Physical therapy or control group.
Physical Therapy Group The women in the standardized physical therapy treatment group will
attend six sessions over a 12-week period. Treatments will be delivered by physical
therapists with post-graduate training in urinary incontinence management. Physical
therapists will have been trained on how to deliver the semi-standardized treatment protocol
at their respective physical therapy clinics in the cities of Ottawa, Kingston or Calgary. In
the first session, volunteers will learn to perform a proper PFM contraction using manual
palpation and feedback to optimize PFM contraction quality in which they will learn to
contract their PFMs before tasks that increase intra-abdominal pressure, such as coughing and
postural perturbations (i.e., the Knack exercise). The women will be instructed to perform
their prescribed exercises daily. At each 45-minute visit, the physical therapist will review
and reinforce a proper PFM contraction technique, will evaluate PFM strength using a modified
Oxford scale to provide feedback about progress, will review the Knack exercise (a quick
contraction of the PFM during high intra-abdominal pressure) and will supervise the volunteer
while she performs each task to ensure correct performance. The exercises will be progressed
and compliance will be recorded as described below.
Control Group Participants in the control group will be asked to follow the recommendations
on their pelvic floor muscle training educational sheet. They will be asked on follow up
visits to report whether or not they attempted PFM exercises and if so, at what frequency.
Post-Intervention/Pre-surgical testing Women in both groups will return to the laboratory 12
weeks after the baseline testing described above. To ensure the evaluators remain blinded to
group assignment, women will be asked not to reveal to the research assistant whether or not
they received physical therapy treatment. The pre-surgical testing will repeat the baseline
testing procedures in the same manner as described above (i.e., bladder diary, pad test, US
imaging, questionnaires), with the exception that the neurological assessment that was
initially used to determine eligibility will not be performed. After this pre-surgical
testing, the women in the physical therapy group will be instructed to continue their
exercise program and will visit their physical therapist every four weeks until their
surgery. Women in the control group will be advised to continue their at-home PFM exercises,
according to the information that was provided on their standard educational sheet.
Post-surgical intervention Only women in the physical therapy group will be advised to
continue their exercise program starting the day after their TVT surgery. Each woman will
visit her physical therapist one week, three weeks and five weeks after her surgery to ensure
she is performing her PFM exercises correctly and to continue the progression of her PFM
exercises according to her progress.
Post-surgical testing All women will return to the laboratory 12 weeks after their surgery
and will be re-evaluated by the research assistant (still blinded to group assignment) using
the ICIQs and the pad test. This post-surgical testing will last 45 minutes.
Long-term follow-up testing All women enrolled in the study will undergo long-term follow up
using the bladder diary, ICIQs and pad test at 12 months and 2 years post-surgery. The ICIQs
can be administered by phone, and this will be done by research assistants whenever patients
cannot attend their follow-up visit(s) in order to reduce the number of participants lost to
follow-up. This will conclude all participation and all women will be mailed or emailed a
research study debriefing sheet outlining the study findings
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04829357 -
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
|
||
Completed |
NCT05493735 -
Lidocaine for Pessary Check Pain Reduction
|
Phase 3 | |
Completed |
NCT04512053 -
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
|
Phase 2 | |
Active, not recruiting |
NCT06224335 -
Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
|
||
Recruiting |
NCT05304312 -
The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women
|
N/A | |
Not yet recruiting |
NCT05527665 -
Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
|
||
Not yet recruiting |
NCT04558762 -
Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
|
||
Withdrawn |
NCT02524366 -
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
|
N/A | |
Completed |
NCT01924728 -
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01676662 -
Solace European Confirmatory Trial
|
N/A | |
Unknown status |
NCT01455779 -
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
|
N/A | |
Terminated |
NCT01029106 -
Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)
|
N/A | |
Completed |
NCT01770691 -
Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01123096 -
Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?
|
N/A | |
Withdrawn |
NCT00573703 -
Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence
|
Phase 4 | |
Completed |
NCT00234754 -
Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women
|
N/A | |
Completed |
NCT00441454 -
Retropubic vs. Transobturator Tension-free Vaginal Tape
|
N/A | |
Completed |
NCT03985345 -
Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.
|
N/A | |
Active, not recruiting |
NCT03671694 -
Laser Vaginal Treatment for SUI
|
N/A | |
Completed |
NCT04097288 -
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
|
Phase 1 |